1
|
Moreno-Pérez O, Reyes-Garcia R, Modrego-Pardo I, Doulatram-Gamgaram VK, Cases CC, Guillen-Morote C, Mendoza NA, Tejera-Pérez C, Cárdenas-Salas J, Martínez-Fuster S, Lardiés-Sánchez B, Márquez-Pardo R, Pinés P, Fernández-García JC. Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO 2 S-RWD). Diabetes Obes Metab 2024; 26:1519-1523. [PMID: 38151966 DOI: 10.1111/dom.15431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 12/11/2023] [Accepted: 12/11/2023] [Indexed: 12/29/2023]
Affiliation(s)
- Oscar Moreno-Pérez
- Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante. Institute of Health and Biomedical Research of Alicante (ISABIAL), Alicante, Spain
- Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain
| | - Rebeca Reyes-Garcia
- Endocrinology Unit. University Hospital of Torrecárdenas, Almería, Spain
- CIBER de Fragilidad y Envejecimiento Saludable "CIBERFES", Instituto de Salud Carlos III, Madrid, Spain
| | - Inés Modrego-Pardo
- Department of Endocrinology and Nutrition, Marina Baixa Hospital, Alicante, Spain
| | - Viyey Kishore Doulatram-Gamgaram
- Department of Endocrinology and Nutrition, Regional University Hospital of Malaga, Biomedical Research Institute of Malaga (IBIMA), Faculty of Medicine, University of Malaga, Malaga, Spain
| | - Carlos Casado Cases
- Department of Endocrinology and Nutrition, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Cristina Guillen-Morote
- Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante. Institute of Health and Biomedical Research of Alicante (ISABIAL), Alicante, Spain
| | - Nieves Arias Mendoza
- Department of Endocrinology and Nutrition, General University Hospital of Elda, Alicante, Spain
| | - Cristina Tejera-Pérez
- Department of Endocrinology and Nutrition, University Hospital Complex of Ferrol, A Coruña, Spain
| | - Jersy Cárdenas-Salas
- Department of Endocrinology and Nutrition, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Sandra Martínez-Fuster
- Department of Endocrinology and Nutrition, General University Hospital of Elda, Alicante, Spain
| | | | - Rosa Márquez-Pardo
- Department of Endocrinology and Nutrition, Hospital Juan Ramón Jiménez, Huelva, Spain
| | - Pedro Pinés
- Albacete University Hospital Complex, Albacete, Spain
| | - José Carlos Fernández-García
- Department of Endocrinology and Nutrition, Regional University Hospital of Malaga, Biomedical Research Institute of Malaga (IBIMA), Faculty of Medicine, University of Malaga, Malaga, Spain
| |
Collapse
|
2
|
Gorgojo-Martinez JJ, Ferreira-Ocampo PJ, Galdón Sanz-Pastor A, Cárdenas-Salas J, Antón-Bravo T, Brito-Sanfiel M, Almodóvar-Ruiz F. Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study. J Clin Med 2023; 12:4248. [PMID: 37445283 DOI: 10.3390/jcm12134248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Revised: 05/30/2023] [Accepted: 06/06/2023] [Indexed: 07/15/2023] Open
Abstract
Aim: This study aimed to evaluate the effectiveness and tolerability of intensifying the dose of canagliflozin from 100 mg/day (CANA100) to 300 mg/day (CANA300) in patients with type 2 diabetes (T2DM) and suboptimal metabolic control in a real-world setting. Methods: A multicenter observational study was conducted on adult patients with T2DM who initiated treatment with CANA100 and subsequently required intensification to CANA300. The primary outcome measures were changes in HbA1c and weight at 6 months after the switch and at the end of the follow-up period. Results: A total of 317 patients met the inclusion criteria (59.6% male, mean age 62.2 years, baseline HbA1c 7.55%, weight 88.6 kg, median duration of treatment with CANA100 9.9 months). Switching to CANA300 resulted in a significant reduction in HbA1c (6 months: -0.33%; last visit: -0.47%, both p < 0.0001) and weight (6 months: -1.8 kg; last visit: -2.9 kg, both p < 0.0001) over a median follow-up period of 20.8 months. The proportion of patients that achieved HbA1c < 7% increased from 26.7% with CANA100 to 51.6% with CANA300 (p < 0.0001). Among individuals with poor baseline glycemic control (HbA1c > 8%, mean 9.0%), HbA1c was significantly reduced by -1.24% (p < 0.0001). Furthermore, significant improvements were observed in fasting plasma glucose (FPG), blood pressure (BP), liver enzymes, and albuminuria. No unexpected adverse events were reported. Conclusions: Intensifying the treatment to CANA300 in a real-world setting resulted in further significant and clinically relevant reductions in FPG, HbA1c, weight, and BP in patients with T2DM. The switch was particularly effective in patients with higher baseline HbA1c levels.
Collapse
Affiliation(s)
- Juan J Gorgojo-Martinez
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
| | - Pablo José Ferreira-Ocampo
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
| | - Alba Galdón Sanz-Pastor
- Department of Endocrinology and Nutrition, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain
| | - Jersy Cárdenas-Salas
- Department of Endocrinology and Nutrition, Fundación Jiménez Díaz, 28040 Madrid, Spain
| | - Teresa Antón-Bravo
- Department of Endocrinology and Nutrition, Hospital Universitario de Móstoles, 28935 Madrid, Spain
| | - Miguel Brito-Sanfiel
- Department of Endocrinology and Nutrition, Hospital Universitario Puerta de Hierro, 28222 Madrid, Spain
| | - Francisca Almodóvar-Ruiz
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
| |
Collapse
|
3
|
Cárdenas-Salas J, Castelo B, Regojo RM, González-Sanchez JA, Álvarez-Escolá C. Long-term complete remission of metastatic adrenocortical carcinoma. Horm Mol Biol Clin Investig 2022; 44:67-71. [PMID: 36069780 DOI: 10.1515/hmbci-2022-0017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Accepted: 07/20/2022] [Indexed: 11/15/2022]
Abstract
OBJETIVES To report a rare case of a metastatic adrenocortical carcinoma (ACC) that achieve a complete and a long-term remission. CASE PRESENTATION AAC is a rare and aggressive tumor, with a high risk of recurrence and that present metastases in 21% of cases at diagnosis. Treatment of advanced ACC is challenging, mitotane is the only available adrenolytic treatment, with modest and unpredictable responses. Response rates to systemic chemotherapy are not encouraging. We describe the case of a 39-year-old woman with a metastatic ACC, that achieve a complete and long-term remission after chemotherapy, mitotane treatment and surgery of primary tumor and liver metastases. CONCLUSIONS A complete remission of a metastatic adrenocortical carcinoma is possible in some rare cases after a multimodal treatment.
Collapse
Affiliation(s)
- Jersy Cárdenas-Salas
- Department of Endocrinology, "Fundación Jiménez-Diaz" University Hospital, Madrid, Spain
| | - Beatriz Castelo
- Department of Oncology, "La Paz" University Hospital, Madrid, Spain
| | - Rita María Regojo
- Department of Pathology, "La Paz" University Hospital, Madrid, Spain
| | | | | |
Collapse
|
4
|
Ruiz-Sánchez JG, Cuesta M, Gómez-Hoyos E, Cárdenas-Salas J, Rubio-Herrera MÁ, Martínez-González E, De Miguel Novoa P, Ternero-Vega JE, Calle-Pascual AL, Runkle I. Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic from Euvolemic Hyponatremia. Medicina (Kaunas) 2022; 58:medicina58070851. [PMID: 35888570 PMCID: PMC9323891 DOI: 10.3390/medicina58070851] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 06/15/2022] [Accepted: 06/22/2022] [Indexed: 01/17/2023]
Abstract
Background and Objectives: Differentiating between hypovolemic (HH) and euvolemic hyponatremia (EH) is crucial for correct diagnosis and therapy, but can be a challenge. We aim to ascertain whether changes in serum creatinine (SC) can be helpful in distinguishing HH from EH. Materials and Methods: Retrospective analysis of patients followed in a monographic hyponatremia outpatient clinic of a tertiary hospital during 1 January 2014−30 November 2019. SC changes during HH and EH from eunatremia were studied. The diagnostic accuracy of the SC change from eunatremia to hyponatremia (∆SC) was analyzed. Results: A total of 122 hyponatremic patients, median age 79 years (70−85), 46.7% women. In total, 70/122 patients had EH, 52/122 HH. During hyponatremia, median SC levels increased in the HH group: +0.18 mg/dL [0.09−0.39, p < 0.001], but decreased in the EH group: −0.07 mg/dL (−0.15−0.02, p < 0.001), as compared to SC in eunatremia. HH subjects presented a higher rate of a positive ∆SC than EH (90.4% vs. 25.7%, p < 0.001). EH subjects presented a higher rate of a negative/null ∆SC than HH (74.3% vs. 9.6%, p < 0.001). ROC curve analysis found an AUC of 0.908 (95%CI: 0.853 to 0.962, p < 0.001) for ∆SC%. A ∆SC% ≥ 10% had an OR of 29.0 (95%CI: 10.3 to 81.7, p < 0.001) for HH. A ∆SC% ≤ 3% had an OR of 68.3 (95%CI: 13.0 to 262.2, p < 0.001) for EH. Conclusions: The assessment of SC changes from eunatremia to hyponatremia can be useful in distinguishing between HH and EH.
Collapse
Affiliation(s)
- Jorge Gabriel Ruiz-Sánchez
- Departamento de Endocrinología, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain;
- Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain; (M.C.); (M.Á.R.-H.); (P.D.M.N.); (A.L.C.-P.); (I.R.)
- Correspondence:
| | - Martín Cuesta
- Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain; (M.C.); (M.Á.R.-H.); (P.D.M.N.); (A.L.C.-P.); (I.R.)
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
| | - Emilia Gómez-Hoyos
- Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain;
| | - Jersy Cárdenas-Salas
- Departamento de Endocrinología, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain;
| | - Miguel Ángel Rubio-Herrera
- Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain; (M.C.); (M.Á.R.-H.); (P.D.M.N.); (A.L.C.-P.); (I.R.)
| | - Estefanía Martínez-González
- Servicio de Análisis Clínicos, Instituto de Medicina de Laboratorio, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain;
| | - Paz De Miguel Novoa
- Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain; (M.C.); (M.Á.R.-H.); (P.D.M.N.); (A.L.C.-P.); (I.R.)
| | | | - Alfonso Luis Calle-Pascual
- Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain; (M.C.); (M.Á.R.-H.); (P.D.M.N.); (A.L.C.-P.); (I.R.)
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain
| | - Isabelle Runkle
- Servicio de Endocrinología y Nutrición, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain; (M.C.); (M.Á.R.-H.); (P.D.M.N.); (A.L.C.-P.); (I.R.)
| |
Collapse
|
5
|
Sierra-Poyatos R, Cárdenas-Salas J, Ortega-Juaristi M, Vázquez-Martínez C. About a rare case of hypoglycemia: Non-islet cell tumor hypoglycemia (NICTH). ENDOCRINOL DIAB NUTR 2021; 68:589-591. [PMID: 34872643 DOI: 10.1016/j.endien.2021.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 07/17/2020] [Indexed: 06/13/2023]
Affiliation(s)
- Roberto Sierra-Poyatos
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
| | - Jersy Cárdenas-Salas
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Maite Ortega-Juaristi
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Clotilde Vázquez-Martínez
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
6
|
Sierra-Poyatos R, Cárdenas-Salas J, Ortega-Juaristi M, Vázquez-Martínez C. About a rare case of hypoglycemia: Non-islet cell tumor hypoglycemia (NICTH). ENDOCRINOL DIAB NUTR 2020; 68:S2530-0164(20)30220-2. [PMID: 33309586 DOI: 10.1016/j.endinu.2020.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Revised: 07/12/2020] [Accepted: 07/17/2020] [Indexed: 11/19/2022]
Affiliation(s)
- Roberto Sierra-Poyatos
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
| | - Jersy Cárdenas-Salas
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Maite Ortega-Juaristi
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Clotilde Vázquez-Martínez
- Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| |
Collapse
|
7
|
Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. Int J Mol Sci 2020; 21:ijms21051682. [PMID: 32121432 PMCID: PMC7084228 DOI: 10.3390/ijms21051682] [Citation(s) in RCA: 96] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2019] [Revised: 02/22/2020] [Accepted: 02/25/2020] [Indexed: 12/14/2022] Open
Abstract
Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors. They should also be considered an effective and safe therapeutic alternative to corticotropinomas, gonadotropinomas, and prolactinomas resistant to dopamine agonists. Somatostatin analogs have also shown to be useful in the treatment of other endocrine diseases (congenital hyperinsulinism, Graves’ orbitopathy, diabetic retinopathy, diabetic macular edema), non-endocrine tumors (breast, colon, prostate, lung, and hepatocellular), and digestive diseases (chronic refractory diarrhea, hepatorenal polycystosis, gastrointestinal hemorrhage, dumping syndrome, and intestinal fistula).
Collapse
Affiliation(s)
- Mariana Gomes-Porras
- Department of Endocrinology, “La Paz” University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain;
| | - Jersy Cárdenas-Salas
- Department of Endocrinology, “Fundación Jiménez-Diaz” University Hospital. Av. de los Reyes Católicos, 2, 28040 Madrid, Spain;
| | - Cristina Álvarez-Escolá
- Department of Endocrinology, “La Paz” University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain;
- Correspondence: ; Tel.: +34-917-277-209
| |
Collapse
|